scPharmaceuticals (NASDAQ:SCPH) Cut to Hold at Maxim Group

Key Points

• Maxim Group has reiterated its "hold" rating for scPharmaceuticals (NASDAQ:SCPH), while Wall Street Zen has upgraded it from "sell" to "hold."
• scPharmaceuticals experienced a 13.7% stock increase recently, reaching $5.5150 with significant trading volume of 16,468,756 shares.
• In its latest earnings report, scPharmaceuticals reported an EPS of ($0.34), missing estimates, but revenues of $16.04 million exceeded expectations.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) was downgraded by equities research analysts at Maxim Group from a "buy" rating to a "hold" rating in a note issued to investors on Monday, MarketBeat reports.

Separately, Wall Street Zen upgraded scPharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $12.00.

scPharmaceuticals Stock Down 0.2%

NASDAQ:SCPH traded down $0.01 during midday trading on Monday, reaching $5.50. 4,384,922 shares of the stock traded hands, compared to its average volume of 1,857,332. scPharmaceuticals has a 12-month low of $1.94 and a 12-month high of $6.28. The business has a 50-day moving average of $4.75 and a two-hundred day moving average of $3.64. The company has a debt-to-equity ratio of 3.86, a quick ratio of 3.14 and a current ratio of 3.85. The stock has a market capitalization of $293.15 million, a PE ratio of -3.04 and a beta of 0.40.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%.The firm had revenue of $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. On average, equities analysts forecast that scPharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Institutional Trading of scPharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SCPH. Rhumbline Advisers raised its stake in shares of scPharmaceuticals by 5.8% during the 2nd quarter. Rhumbline Advisers now owns 54,500 shares of the company's stock valued at $208,000 after buying an additional 3,001 shares during the last quarter. Lido Advisors LLC boosted its holdings in scPharmaceuticals by 14.6% in the 2nd quarter. Lido Advisors LLC now owns 27,500 shares of the company's stock worth $105,000 after buying an additional 3,500 shares during the last quarter. Captrust Financial Advisors boosted its holdings in scPharmaceuticals by 9.0% in the 2nd quarter. Captrust Financial Advisors now owns 43,746 shares of the company's stock worth $167,000 after buying an additional 3,621 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in scPharmaceuticals by 63.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,336 shares of the company's stock worth $36,000 after buying an additional 3,628 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in scPharmaceuticals by 9.0% in the 4th quarter. Bank of America Corp DE now owns 44,037 shares of the company's stock worth $156,000 after buying an additional 3,647 shares during the last quarter. Institutional investors and hedge funds own 89.52% of the company's stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.